Rapid Micro Biosystems Inc
NASDAQ:RPID
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Rapid Micro Biosystems Inc
Total Liabilities & Equity
Rapid Micro Biosystems Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rapid Micro Biosystems Inc
NASDAQ:RPID
|
Total Liabilities & Equity
$74.9m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Liabilities & Equity
$110.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Liabilities & Equity
$83.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
Waters Corp
NYSE:WAT
|
Total Liabilities & Equity
$5.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
2%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Liabilities & Equity
$12.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Liabilities & Equity
$29.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
23%
|
|
Rapid Micro Biosystems Inc
Glance View
Rapid Micro Biosystems, Inc. is an innovative life sciences technology company. The company is headquartered in Lowell, Massachusetts and currently employs 220 full-time employees. The company went IPO on 2021-07-15. The firm provides automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct platform automates and modernizes the manual microbial quality control (MQC), testing workflows used in pharmaceutical manufacturing operations across the globe. The Growth Direct platform helps on the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver results with data regulations, and decision making that its customers rely on to ensure the supply of healthcare products. The Company’s Growth Direct platform is the automated MQC solution. The firm offers two consumables plates to capture test samples for analysis on the Growth Direct, which includes an Environmental Monitoring (EM), consumable and a Water/Bioburden (W/BB) consumable.
See Also
What is Rapid Micro Biosystems Inc's Total Liabilities & Equity?
Total Liabilities & Equity
74.9m
USD
Based on the financial report for Dec 31, 2025, Rapid Micro Biosystems Inc's Total Liabilities & Equity amounts to 74.9m USD.
What is Rapid Micro Biosystems Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
-27%
Over the last year, the Total Liabilities & Equity growth was -24%. The average annual Total Liabilities & Equity growth rates for Rapid Micro Biosystems Inc have been -27% over the past three years .
